At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 367 enrolled
Drug / intervention
Pazopanib +1 moredrug
Likely dose
Pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma - A Substudy to VEG108844
In Brief
A Phase 2 clinical trial evaluating Pazopanib and Sunitinib for Carcinoma, Renal Cell. Completed, enrolled 367 participants across 21 sites in 3 countries.
Detailed Summary
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior systemic therapy for advanced or metastatic RCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesChina, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionMay 2012
Study CompletionSep 2021
TodayJul 2026
First PostedJun 22, 2010
Enrollment StartMay 19, 2010
Primary CompletionMay 21, 2012
Study CompletionSep 3, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 16.0 years ago
Interventions
Pazopanibdrug
800 mg administered once daily orally continuous dosing
Sunitinibdrug
50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment